<DOC>
	<DOC>NCT01365546</DOC>
	<brief_summary>Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.</brief_summary>
	<brief_title>Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Diagnosed with congenital VWD (von Willebrand Disease) Require therapy with a VWF (von Willebrand Factor) product to treat any major surgical procedure Known coagulation disorder other than VWD Known history of, or suspected VWF or FVIII inhibitors Subjects with hepatic liver disease Known or suspected hypersensitivity or previous evidence of severe side effects to wilate or other VWF/FVIII concentrates Pregnant women in the first 20 weeks of gestation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>